OncoMatch/Clinical Trials/NCT06035757
The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery
Is NCT06035757 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Bridion 200 MG in 2 ML and Pyridostigmine Bromide 5 MG/ML for emergence delirium.
Treatment: Bridion 200 MG in 2 ML · Pyridostigmine Bromide 5 MG/ML — The present trial conducted to demonstrate the administration of sugammadex as reversal of neuromuscular blockade agent reduces the incidence of emergence agitation (EA) comparing to neostigmine
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Performance status
ASA 1–2
Lab requirements
Kidney function
no impaired kidney function
Liver function
no impaired liver function
Cardiac function
no cardiovascular disease or arrhythmia
impaired liver function; impaired kidney function; cardiovascular disease or arrhythmia [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify